title: A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).
abstract: OBJECTIVE
  A multicenter, nonrandomized, phase II study was initiated to evaluate the tolerability, toxicity, and activity of paclitaxel, carboplatin, and gemcitabine combination in previously untreated ovarian cancer.
  
  
  METHODS
  Chemonaive patients who had radical debulking surgery for primary epithelial ovarian cancer International Federation of Gynecology and Obstetrics (FIGO) IC-IV received sequentially paclitaxel 175 mg/m(2), carboplatin AUC 5, and gemcitabine 800 mg/m(2) on day 1 and gemcitabine 800 mg/m(2) on day 8, every 3 weeks.
  
  
  RESULTS
  From October 2001 to July 2002, 55 patients were treated and evaluated. Main toxicities were hematological with NCI-CTC grade 3/4 anemia 12.7%, leukopenia 70.9%, neutropenia 76.3%, and thrombocytopenia 45.5. However, febrile neutropenia occurred only in 1.8%. Grade 3/4 nonhematological toxicities were rare and occurred in less than 10% of patients. Toxicity-induced treatment delays occurred in 3.1% of cycles and resulted in early treatment cessation in four patients. Dose intensity reached 90.8% for carboplatin and paclitaxel, and 73.3% for gemcitabine. Objective response was observed in 10 of 14 patients with measurable disease.
  
  
  CONCLUSIONS
  The triplet combination of paclitaxel-carboplatin-gemcitabine is feasible and active, with manageable hematological toxicity and no unexpected nonhematological toxicity. This regimen has proceeded to phase III evaluation.
authors.affiliation: Department of Gynecology and Gynecologic Oncology, and AGO Study Secretary, Dr. Horst Schmidt Klinik Wiesbaden (HSK), Ludwig-Erhard-Str. 100, D-65199 Wiesbaden, Germany. dubois.hsk-wiesbaden@uumail.de
authors.forename: A
authors.initials: A
authors.lastname: du Bois
authors.forename: A
authors.initials: A
authors.lastname: Belau
authors.forename: U
authors.initials: U
authors.lastname: Wagner
authors.forename: J
authors.initials: J
authors.lastname: Pfisterer
authors.forename: B
authors.initials: B
authors.lastname: Schmalfeldt
authors.forename: B
authors.initials: B
authors.lastname: Richter
authors.forename: A
authors.initials: A
authors.lastname: Staehle
authors.forename: C
authors.initials: C
authors.lastname: Jackisch
authors.forename: H J
authors.initials: HJ
authors.lastname: Lueck
authors.forename: W
authors.initials: W
authors.lastname: Schroeder
authors.forename: A
authors.initials: A
authors.lastname: Burges
authors.forename: S
authors.initials: S
authors.lastname: Olbricht
authors.forename: G
authors.initials: G
authors.lastname: Elser
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D018572:Disease-Free Survival; D004847:Epithelial Cells / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D016190:Carboplatin; D017239:Paclitaxel; D000093542:Gemcitabine